Drug Delivery Device Articles & Analysis
22 news found
Watertown, MA - June 29, 2025 - Biopharma PEG, a leading innovator in high-quality polyethylene glycol (PEG) derivatives, today announced it has successfully obtained Drug Master File (DMF) approval from the U.S. Food and Drug Administration (FDA) for its self-developed HZ-PEG-HZ (1K) product. ...
Key Product Highlights: · PEG Derivatives o A vast inventory of over 3000 high-quality PEG derivatives. o Monodispersed PEG linkers and multi-arm PEGs. o Scalable production from R&D to GMP commercial levels. o Applications spanning ADCs, PROTACs, LNP drug delivery, medical devices, and more. · Pharmaceutical Intermediates o ...
These hydrogels are pivotal in medical devices, regenerative medicine, drug delivery systems, 3D cell culture, and wound healing." ...
Biomedical Polymers Biomedical polymers have and still continue to play an important role in how we support and treat patients with various diseases through their use in tissue and blood interacting medical devices and drug delivery systems. Electrofunctional Polymers Conducting electroactive polymers such as polypyrroles, polythiophenes and ...
Nasaldrugdeliveryblog.com opens lines of communication between drug delivery researchers, device manufacturers. The first blog to address issues related to nasal drug delivery formulation, research, delivery, and devices was launched by Kurve Technology, Inc., a leading ...
Broomfield Colorado 6/16/2022. Aktiv Pharma Group (Aktiv) announced today the acceptance of its novel glass-free, film-based flexible primary drug container (PDC) technology for sterile injectables named ARCH, into the US Food and Drug Administration (FDA) Emerging Technology Program (ETP). The ETP is a collaborative effort which supports the FDA’s mission to facilitate modernization in ...
(PRWEB) August 23, 2022 Nob Hill Therapeutics (NHT), a VIC Technology Venture Development portfolio company, announced today that it has received an HHS phase II grant (up to $1.73M) to develop an inhaled therapy to treat lung fungal infection using an innovative first-of-its-kind dry powder nebulizer delivery platform technology. The funds will be used to develop the ...
ApiJect is developing an innovative portfolio of drug delivery devices using high-speed BFS manufacturing, which is recognized by the FDA as an advanced aseptic process that forms, fills and seals a single unit dose in a continuous, automated manufacturing step. ...
Berkshire Biomedical Corporation (“Berkshire” or “the Company”), focused on developing drug delivery devices designed to accurately and precisely deliver oral liquid drugs only to the biometrically authenticated Intended User, provide remote monitoring and enhance patient wellness, announced today that ...
Berkshire Biomedical, LLC (“Berkshire” or “the Company”), focused on developing drug delivery devices designed to precisely deliver oral liquid drugs only to the biometrically authenticated Intended User, provide remote monitoring and enhance patient wellness, announces today that it joins with the ...
Bexson Biomedical, Inc., a research-stage company developing therapies and delivery solutions for pain management, addiction and mental health indications, announced today that the U.S. ...
As Senior VP, Drug Delivery, Moberg will lead the development of Bexson's drug delivery technologies, starting with a wearable infusion device for its BB106 therapy, in partnership with Italian drug containment solution and medical device manufacturer, Stevanato Group. ...
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has received approval from the U.S. Food and Drug Administration for its Investigational Device Exemption application for its vascular sealant. The approval is the most recent validation of TISSIUM’s efforts to ...
ByTISSIUM
Laughner served as the Associate Director, Combination Products at MedImmune, an AstraZeneca company, where he developed regulatory strategies and submissions for combination products in their biologic portfolio and developed strategies to evaluate the safety and effectiveness of drug delivery systems, including novel and wearable technologies. Prior to ...
The currently accepted procedure is, to use drug delivery devices to deliver drugs that inhibit the inflammatory and proliferative pathways that lead to restenosis. Sirolimus is widely accepted as a drug of choice for such a purpose. Several studies have demonstrated that Erectile Dysfunction (ED) is ...
“Endomedix has developed a novel polysaccharide chemistry platform that will be used to develop a series of differential biosurgical devices, ranging from game changing absorbable hemostats to specialty wound treatments to tissue sealants and sustained released devices. ...
This article addresses the method development and verification necessary to use a variable natural material as a key component in a consistent medical device. “Working with natural biomaterials as components or substrates for medical devices holds great promise from the perspectives of biocompatibility, biodegradation and nontoxicity”, notes Richard ...
Unlike currently available hemostats that require continuous manual pressure to be effective, the Endomedix device can spray or flow on without manual pressure and stays in place. ...
“A recent review of published reports of hemostat device performance did not locate any findings about stable clot formation or coagulation produced by these hemostats”, added Ms. ...
Though the underlying technology allows inclusion of drugs in the product formulation, the hemostat does not include any drugs or chemicals. ...